Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mibavademab
- Development stage
- Phase 3
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Mibavademab is a fully human monoclonal antibody that acts as an agonist of the leptin receptor (LEPR). It is being developed by Regeneron Pharmaceuticals for the treatment of conditions associated with leptin deficiency, including congenital or acquired generalized lipodystrophy, familial partial lipodystrophy, and obesity. Mibavademab is designed to mimic the action of leptin by activating its receptor, thereby addressing metabolic abnormalities in patients with leptin deficiency or resistance. The drug has received orphan drug designation for lipodystrophy in both the US and Europe. Clinical studies have evaluated intravenous and subcutaneous administration routes in both pediatric and adult populations[1][2][4][5][7].
- Brand names
- mibavademab
- Other names
- REGN4461REGN-4461REGN 4461mibavademab
02
Targets
LEPR (Leptin receptor)
Beyond the preview
Go deeper on mibavademab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mibavademab.